Full text
Earnings transcript
Read the complete earnings call transcript.
4528
4528.T
Ono Pharmaceutical Co., Ltd.
$2350
21
(0.9%)
| Exchange: | JPX |
| Market Cap: | 1.104T |
| Shares Outstanding: | 499.137M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Gyo Sagara | |||||
| Full Time Employees: | 3853 | |||||
| Address: |
| |||||
| Website: | https://www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company’s offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer’s disease and ONGENTYS tablets for Parkinson’s disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin’s lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 502,672,000 | 486,871,000 | 515,785,000 |
| Gross Profit | 372,665,000 | 335,469,000 | 374,069,000 |
| EBITDA | 181,979,000 | 87,857,000 | 133,945,000 |
| Operating Income | 163,561,000 | 63,384,000 | 103,335,000 |
| Net Income | 127,978,000 | 50,047,000 | 69,767,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 913,668,000 | 1,064,046,000 | 1,106,515,000 |
| Total Liabilities | 115,063,000 | 275,843,000 | 249,872,000 |
| Total Stockholders Equity | 792,961,000 | 782,451,000 | 850,727,000 |
| Total Debt | 8,862,000 | 146,678,000 | 120,935,000 |
| Cash and Cash Equivalents | 166,141,000 | 204,567,000 | 237,046,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 110,660,000 | 82,459,000 | 136,821,000 |
| Capital Expenditure | -4,020,000 | -5,431,000 | -6,024,000 |
| Free Cash Flow | 106,640,000 | 77,028,000 | 130,797,000 |
| Net Income | 127,978,000 | 50,047,000 | 69,767,000 |
| Net Change in Cash | 70,006,000 | 38,426,000 | 32,479,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 474,656,798.208 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 505,282,130.735 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 486,060,750 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 142,617,590.107 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 151,819,420.014 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 146,044,074.524 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 63,208,325.007 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 68,548,555.758 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 65,196,865.838 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 102,852,923.396 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 109,489,097.137 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 105,324,034.701 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 138.730 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 145.860 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 134.490 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 4 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about 4528.T valuation
Is Ono Pharmaceutical Co., Ltd. (4528.T) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Ono Pharmaceutical Co., Ltd. (4528.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 4528.T a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4528.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 4528.T’s P/E ratio?
You can see 4528.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 4528.T?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 4528.T a good long-term investment?
Whether 4528.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
4528.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.9
Trading Metrics:
| Open: | 2326 | Previous Close: | 2329 | |
| Day Low: | 2323 | Day High: | 2364.5 | |
| Year Low: | 1532 | Year High: | 2674.5 | |
| Price Avg 50: | 2350.05 | Price Avg 200: | 2210.96 | |
| Volume: | 1.428M | Average Volume: | 1.819M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free